Multi-District Lawsuit Alleges GLP-1 Weight Loss Drugs Cause Permanent Blindness
A multi-district lawsuit, comprising over 130 cases, is currently before a Philadelphia judge, claiming that popular GLP-1 medications, including Wegovy, Ozempic, Mounjaro, and Zepbound, are linked to a rare and permanent form of vision loss known as non-arteritic anterior ischemic optic neuropathy (NAION). This irreversible condition, often described as an eye stroke, is caused by restricted blood flow. The lawsuit targets drug manufacturers Novo Nordisk and Eli Lilly. A 2024 study published in JAMA Ophthalmology by researchers at Mass Eye and Ear in Boston indicated that diabetic patients prescribed GLP-1 medications were more than four times more likely to be diagnosed with NAION, while overweight patients taking the drugs were more than seven times more likely to receive the diagnosis. Attorney Jason Goldstein, serving on the lawsuit's steering committee, highlighted that NAION strikes suddenly and without warning, leading to permanent vision loss. One plaintiff, Diane Wirth, a former nurse practitione...